bluuebunny/crossref_metadata_2025_split huggingface dataset:
Idiotype‐pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival
Authors: Lacy Martha Q. , Mandrekar Sumithra , Dispenzieri Angela , Hayman Suzanne , Kumar Shaji , Buadi Francis , Dingli David , Litzow Mark , Wettstein Peter , Padley Douglas , Kabat Brian , Gastineau Dennis , Rajkumar S. Vincent , Gertz Morie A. 
Published: October 2009

AbstractVaccines are attractive as consolidation therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We report the results of a phase II trial of the immunotherapeutic, APC8020 (Mylovenge™), given after ASCT for MM. We compared the results with that of other patients with MM who underwent ASCT at Mayo Clinic during the same time period. Twenty‐seven patients were enrolled on the trial between July, 1998 and June, 2001, and the outcomes were compared to that of 124 consecutive patients transplanted during the same period, but not enrolled on the trial. The median (range) follow‐up for patients still alive from the vaccine trial is 6.5 (2.9–8 years), and 7.1 (6–8 years) in the control group. The median age was 57.4 range (36.1–71.3) in the DB group and 56.4 (range, 30–69) in the trial group. Known prognostic factors including PCLI, B2M, and CRP were comparable between the groups. The median overall survival for the trial patients was 5.3 years (95% CI: 4.0 years—N/A) compared to 3.4 years (95% CI: 2.7–4.6 years) for the DB group (P = 0.02). The median time to progression and progression‐free survival for the trial group was similar to the DB group. Although not a controlled trial, the vaccines given after ASCT appear to be associated with improved overall survival compared to historical controls. This approach warrants further investigation to confirm this and define the role of vaccine therapy in myeloma. Am. J. Hematol. 2009. © 2009 Wiley‐Liss, Inc.
Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon‐alpha, hydroxyurea, imatinib mesylate or 2‐chlorodeoxyadenosine
Authors: Lim Ken H. , Pardanani Animesh , Butterfield Joseph H. , Li Chin‐Yang , Tefferi Ayalew 
Published: October 2009

AbstractCytoreductive therapy in systemic mastocytosis (SM) includes several drugs whose individual merit has not been well characterized. We retrospectively studied 108 Mayo Clinic patients who met the 2008 WHO diagnostic criteria for SM and received at least one cytoreductive drug. The numbers of patients who were evaluable for response to treatment with interferon‐alpha with or without prednisone (IFN‐α), hydroxyurea (HU), imatinib mesylate (IM) or 2‐chlorodeoxyadenosine (2‐CdA) were 40, 26, 22, and 22, respectively. The corresponding overall (major) response rates, according to recently published consensus criteria, were 53% (18%), 19% (0%), 18% (9%), and 55% (37%). The respective overall response rates in indolent SM, aggressive SM and SM associated with another clonal hematological nonmast cell lineage disease (SM‐AHNMD) were 60%, 60%, 45% for IFN‐α, 0, 0, 21% for HU, 14%, 50%, 9% for IM and 56%, 50%, 55% for 2‐CdA. The absence of mast cell mediator release symptoms in IFN‐α‐treated patients and presence of circulating immature myeloid cells in 2‐CdA‐treated patients predicted inferior response. TET2 mutational status did not influence treatment response. Although the major response rates with these four cytoreductive agents were still suboptimal and HU was mainly used in patients with SM‐AHNMD, the current study favors 2‐CdA or IFN‐α as first‐line current therapy in SM and identifies patients who are likely to respond to such therapy. Am. J. Hematol., 2009. © 2009 Wiley‐Liss, Inc.
Static magnetic field exposure fails to affect the viability of different bacteria strains
Authors: László János , Kutasi József 
Published: October 2009

AbstractThe viability of the microbes Saccharomyces cerevisiae, Bacillus circulans, Escherichia coli, Micrococcus luteus, Pseudomonas fluorescens, Salmonella enteritidis, Serratia marcescens, and Staphylococcus aureus was tested under static magnetic field exposure up to 24 h in either a homogeneous (159.2 ± 13.4 mT) or three types of inhomogeneous static magnetic fields: (i) peak‐to‐peak magnetic flux density 476.7 ± 0.1 mT with a lateral magnetic flux density gradient of 47.7 T/m, (ii) 12.0 ± 0.1 mT with 1.2 T/m, or (iii) 2.8 ± 0.1 mT with 0.3 T/m. Even the longest period of exposure failed to produce any effect in the growth of bacteriae that could be correlated with static magnetic field exposure. Bioelectromagnetics 31:220–225, 2010. © 2009 Wiley‐Liss, Inc.
Comparison of 2‐year clinical outcomes with sirolimus and paclitaxel‐eluting stents for patients with diabetes: Results of the Registro Regionale AngiopLastiche Emilia‐Romagna Registry
Authors: Balducelli Marco , Ortolani Paolo , Marzaroli Paolo , Piovaccari Giancarlo , Menozzi Alberto , Manari Antonio , Sangiorgio Pietro , Tarantino Fabio , Rossi Rosario , Maresta Aleardo , Tondi Stefano , Passerini Francesco , Guastaroba Paolo , Grilli Roberto , Marzocchi Antonio 
Published: October 2009

AbstractBackground: Long‐term outcomes of percutaneous coronary interventions (PCI) with sirolimus‐eluting stents (SES) compared to paclitaxel‐eluting‐stents (PES) in unselected diabetics in routine practice is still debated. Objective: This study compared the 2‐year incidence of MACE (all‐cause mortality, nonfatal myocardial infarction and target vessel revascularization) of SES and PES in a real‐world setting of patients with diabetes. Design: Observational, multicenter, nonrandomized study. Setting: Prospective web‐based registry (REAL Registry; study period, 2002–2005) comprising all 13 hospitals performing PCI. Patients: Among the 945 eligible patients treated with either SES alone (n = 606) or PES alone (n = 339), 29% were insulin‐requiring, 72% had multivessel coronary disease, 26% had prior myocardial infarction and 10% had poor left ventricular function. Measurements: Unadjusted and propensity score‐adjusted 2‐year clinical outcome. Results: After propensity score adjustment, 2‐year MACE incidence in the SES and PES groups was equivalent (23.3% vs. 23.7%, HR 1.01, 95%CI 0.72–1.42, P = 0.96). Adjusted 2‐year angiographic stent thrombosis occurred in 1.1% of the SES patients versus 2.6% of the PES patients (P = 0.15). In this large, real‐world, diabetic population treated with DES, there was no difference in outcome between SES and PES. Further studies are needed to demonstrate the long‐term safety of different types of DES in patients with diabetes. © 2009 Wiley‐Liss, Inc.
Long term clinical outcomes after deployment of femoral vascular closure devices in coronary angiography and percutaneous coronary intervention
Authors: Lee Stephen Wai‐Luen , Ho Hee‐Hwa , Kong Shun‐Ling , Lam Yui‐Ming , Siu Chung‐Wah , Miu Kin‐Man , Lam Linda , Chan Hon‐Wah 
Published: October 2009

AbstractBackground: We evaluated the long term clinical outcomes of femoral vascular closure devices following its deployment in coronary angiography and percutaneous coronary intervention (PCI) procedures. Methods: From June 2000 to September 2004, 265 patients who received femoral vascular closure devices after coronary angiography and PCIs were enrolled into the study. Patients' medical records were reviewed and vascular complications within 1 year of follow‐up period were recorded. Rutherford's categories of claudication were used to quantify different degrees of claudication and leg ischaemia. Duplex ultrasonography of both femoral arteries (using the nonaccessed site as control) was performed at 1 year after deployment of vascular closure devices. Vessel diameter and flow velocities for both common femoral arteries were obtained. Results: There was no occurrence of late vascular complications like arteriovenous fistula, pseudoaneurysm, surgical repair of access site complications, late groin bleeding and infection. By Rutherford categories of claudication, 99.2% of patients had grade 0 claudication while the remaining 0.8% was in grade 1. By arterial Duplex ultrasonography, the peak systolic velocity of the accessed femoral artery (predominantly right side) was nonsignificantly higher, 94.9 ± 26.0 cm/s when compared to 91.5 ± 24.8 cm/s in the control site (P = 0.12). As for vessel diameter, no significant difference was found in the mean end‐diastolic vessel diameter 8.8 ± 1.3 mm (puncture site) versus 8.7 ± 4.4 mm (control site) (P = 0.72). Conclusion: We found that the use of femoral closure devices was safe and it was not associated with any adverse long term vascular complications. © 2009 Wiley‐Liss, Inc.
TIMI myocardial perfusion frame count: A new method to assess myocardial perfusion and its predictive value for short‐term prognosis
Authors: Ding Song , Pu Jun , Qiao Zhi‐qing , Shan Peiren , Song Wei , Du Yongping , Shen Jie‐Yan , Jin Shu‐xuan , Sun Yu , Shen Long , Lim Yean‐leng , He Ben 
Published: October 2009

AbstractObjectives: We sought to develop a new quantitative method to evaluate the degree of myocardial perfusion. Background: Currently available methods for assessing myocardial perfusion, both TIMI myocardial perfusion grading (TMPG) and myocardial blush grading (MBG), are subjective. Methods: TIMI Myocardial Perfusion Frame Count (TMPFC), an objective method that measures the filling and clearance of contrast in the myocardium using cine‐angiographic frame‐counting, was developed to quantify myocardial perfusion. Myocardial perfusion of 45 normal coronary arteries in 15 patients, and 137 culprit arteries in 137 patients immediately after primary angioplasty, was successfully assessed with TMPFC. Results: The mean TMPFC in the normal arteries was 83.47 ± 17.96 frames (95% CI: 78.07 frames ≤ TMPFC ≤ 88.86 frames). Therefore, TMPFC < 90 frames, a value representing the upper bound of the 95% CI for the TMPFC observed in normal arteries, was defined as normal myocardial perfusion. In 137 culprit arteries, the mean TMPFC values after primary angioplasty for the right coronary artery (RCA), left anterior descending artery (LAD), and left circumflex artery (LCX) were 141 ± 82.6, 112 ± 80.3, and 102 ± 37.5 frames, respectively. Patients with suboptimal myocardial perfusion (ex: TMPG ≤ 2 or MBG ≤ 2 grade) had higher levels of TMPFC. Furthermore, multivariate analysis shows that the TMPFC was an independent predictor for 30‐day (P = 0.0261) and 6‐month incidence of MACE (P = 0.0207). Conclusions: TMPFC is a quantitative index for the assessment of myocardial perfusion; it allows quantification of TMPG and may serve as a discerning tool to predict prognosis in patients undergoing primary angioplasty. © 2009 Wiley‐Liss, Inc.
Clinical cerebrovascular anatomy
Authors: Krishnaswamy Amar , Klein Joshua P. , Kapadia Samir R. 
Published: October 2009

AbstractStroke is often the result of carotid atheroma, which may cause ischemia via progressive arterial narrowing or lead to superimposed thrombus formation and subsequent atheroembolism to the intracerebral vasculature. Revascularization through carotid endarterectomy or carotid artery stenting with embolic protection devices has produced favorable results in appropriately selected patients. In planning the percutaneous approach, an arch aortogram is first acquired to determine arch type and identify the presence of any anatomic variants which may affect the approach to the procedure and catheter selection. Subsequent imaging of the cerebral vasculature is performed to delineate the collateral circulation that is present, including an evaluation of the Circle of Willis. Although Doppler ultrasound, computed tomography (CT), and magnetic resonance angiography (MRA) may be useful in evaluating the presence of carotid or cerebrovascular disease, digital subtraction angiography is required prior to performance of a percutaneous intervention in order to create a procedural “roadmap”. Additionally, the comprehensive management of cerebrovascular disease requires a detailed knowledge of the specific clinical syndromes that result from ischemia in each vascular territory. This methodical review of cerebrovascular anatomy and stroke syndromes will provide the operator with the tools to conduct a thorough neurological assessment prior to revascularization, evaluate any periprocedural complications that may arise, and evaluate the patient with suspected stroke. © 2009 Wiley‐Liss, Inc.
Left main intervention in myocardial infarction
Authors: Castagna Marco T. , Machado Mauricio Cavalieri , de Oliveira Jordan Vieira 
Published: October 2009

AbstractWe report an 84‐year‐old patient who suddenly developed nausea, vomiting, hypotension, and needed intubation, assisted ventilation and pharmacological vasopressor support. Admission EKG showed anterior and lateral leads ST segment depression and 2 mm ST segment elevation in avR lead. Angiogram showed unprotected left‐main coronary‐artery (LM) sub‐occlusive disease and totally occluded ostial right‐coronary‐artery (RCA), distally filled through the left‐coronary system. Unprotected LM disease was immediately treated with bare metal stent. The stent jailed the left‐circunflex coronary‐artery (LCx) ostium but did not compromise the arterial flow. Lately, the patient was discharged in a very good health condition. Ten months angiographic follow‐up showed an extremely compromised LCx ostium treated successfully with drug eluted stent (DES) and mid left anterior descendent (LAD) severe lesion, treated with DES. © 2009 Wiley‐Liss, Inc.
Three‐year outcome of drug‐eluting stent implantation for coronary artery bifurcation lesions
Authors: Stinis Curtiss T. , Hu Stephen P.C. , Price Matthew J. , Teirstein Paul S. 
Published: October 2009

AbstractObjectives: To compare the very long‐term clinical outcomes of bifurcation lesions using the crush and the simultaneous kissing stent (SKS) techniques. Background: A variety of two‐stent techniques have been used to treat coronary artery bifurcation lesions in the drug‐eluting stent era, but the long‐term clinical outcome of these approaches is not known. Methods: A total of 74 consecutive patients underwent bifurcation stenting using either the crush or SKS techniques. Mean patient age was 66.91 ± 11.3 years; 26% were diabetic, and the left anterior descending/diagonal bifurcation was the most frequently treated lesion (68%). Results: In‐hospital outcomes were not significantly different between groups. Over a median follow‐up of 3.3 years, 1 patient in the SKS group and 3 patients in the crush group died (P = ns). Probable stent thrombosis leading to death according to the Academic Research Consortium definition occurred in 1 patient in the crush group. Mortality in the remaining 3 patients was noncardiac. Target lesion revascularization (TLR) occurred in 14 patients (40%) in the SKS group and 5 patients (12.8%) in the crush group (P = 0.015). Survival free from major adverse cardiac events (MACE) was significantly less in the SKS group and predominantly driven by TLR (60 vs. 88%, P = 0.001). Conclusions: In conclusion, over a median of 3.3 years of follow‐up, TLR and MACE are significantly lower in bifurcation lesions treated with the crush technique when compared with the SKS technique. Definite or probable stent thrombosis is rare with either technique. © 2009 Wiley‐Liss, Inc.
Mesoporous Silica Nanosphere‐Supported Chiral Ruthenium Catalysts: Synthesis, Characterization, and Asymmetric Hydrogenation Studies
Authors: Mihalcik David J. , Lin Wenbin 
Published: October 2009

AbstractChiral RuCl2–diphosphine–diamine complexes with a pendant siloxy group were synthesized and characterized by NMR spectroscopy and mass spectrometry. The Ru complexes were grafted onto three different types of mesoporous silica nanospheres (MSNs) through the siloxane linkage, and the resulting MSN‐supported Ru catalysts were highly active for the asymmetric hydrogenation of aromatic ketones, to afford chiral secondary alcohols, and racemic arylaldehydes, to give chiral primary alcohols. Excellent activities and enantioselectivities were observed for these MSN‐supported Ru catalysts owing to readily accessible and uniform catalytic sites within the large channels of MSNs (diameters of >2 nm) and short diffusion lengths for the organic compounds as a result of small nanoparticle sizes of less than 1 μm. This catalyst immobilization strategy with MSN supports should be amenable to the design of many highly active and enantioselective heterogeneous asymmetric catalysts.
Improved Molecular Weight Control in Ring‐Opening Metathesis Polymerization (ROMP) Reactions with Ru‐Based Olefin Metathesis Catalysts Using N Donors and Acid: A Kinetic and Mechanistic Investigation
Authors: Dunbar Miles A. , Balof Shawna L. , LaBeaud Lawrence J. , Yu Bing , Lowe Andrew B. , Valente Edward J. , Schanz Hans‐Jörg 
Published: October 2009

AbstractThe effect of the addition of H3PO4 on the ROMP activity of cyclooctene (COE) with first‐ [Cl2(PCy3)2RuCHPh] and second‐generation [(H2IMes)Cl2(PCy3)RuCHPh] Grubbs’ catalysts 1 and 4 (Cy=cyclohexyl, Ph=phenyl, Mes=2,4,6‐trimethylphenyl (mesityl)), their inhibited mixtures with 1‐methylimidazole (MIM), as well as their isolated bis‐N,N′‐dimethylaminopyridine (DMAP) derivatives [Cl2(PCy3)(DMAP)2RuCHPh)] (5 b) and [Cl2(H2IMes)(DMAP)2RuCHPh] (7 b) (DMAP=dimethylaminopyridine), a novel catalyst, has been investigated. The studies include the determination of their initiation rates, as well as a determination of the molecular weights and molecular weight distributions of the polymers obtained with these catalysts and catalyst mixtures from the exo‐7‐oxanorbornene derivative 11. The structure of catalyst 7 b was confirmed by means of X‐ray diffraction. All N‐donor‐bearing catalysts or N‐donor‐containing catalyst mixtures not only exhibited elevated activity in the presence of acid, but also increased initiation rates. Using the reversible inhibition/activation protocol with MIM and H3PO4 enabled us to conduct controlled ROMP with catalyst 4 producing the isolated exo‐7‐oxanorbornene‐based polymer 12 with predetermined molecular weights and narrow molecular weight distributions. This effect was based on fast and efficient catalyst initiation in contrast to the parent catalyst 4. Hexacoordinate complex 5 b also experienced a dramatic increase in initiation rates upon acid‐addition and the ROMP reactions became well‐controlled in contrast to the acid‐free reaction. In contrast, complex 7 b performs well‐controlled ROMP in the absence of acid, whereas the polymerization of the same monomer becomes less controlled in the presence of H3PO4. The closer evaluation of catalysts 5 b and 7 b demonstrated that their initiation rates exhibit a linear dependency on the substrate concentration in contrast to catalysts 1 and 4. As a consequence, their initiation rates are determined by an associative step, not a dissociative step as seen for catalysts 1 and 4. A feasible associative metathesis initiation mechanism is proposed.
Divergent Syntheses of Resorcylic Acid Lactones: L‐783277, LL‐Z1640‐2, and Hypothemycin
Authors: Dakas Pierre‐Yves , Jogireddy Rajamalleswaramma , Valot Gaëlle , Barluenga Sofia , Winssinger Nicolas 
Published: October 2009

AbstractThe resorcylic acid lactones (RAL) are endowed with diverse biological activity ranging from transcription factor modulators (zearalenone and zearalenol) to HSP90 inhibitors (radicicol and pochonin D) and reversible (aigialomycin D) as well as irreversible kinase inhibitors (hypothemycin and other RAL containing a cis‐enone). Our interest in broadening the diversity of this family beyond naturally occurring diversity has led us to seek a general approach that could be used to address the entire spectrum of functionalities present within this family. Herein, we present our efforts on accessing macrocycles bearing an alkane, alkene, or epoxide at the benzylic position from a common benzylic sulfide intermediate to access L‐783277, LL‐Z1640‐2, and hypothemycin.
Ambident PCN Heterocycles: N‐ and P‐Phosphanylation of Lithium 1,3‐Benzazaphospholides
Authors: Aluri Bhaskar R. , Burck Sebastian , Gudat Dietrich , Niemeyer Mark , Holloczki Oldamur , Nyulaszi Laszlo , Jones Peter G. , Heinicke Joachim 
Published: October 2009

AbstractSynthetic and structural aspects of the phosphanylation of 1,3‐benzazaphospholides 1Li, ambident benzofused azaphosphacyclopentadienides, are presented. The unusual properties of phospholyl‐1,3,2‐diazaphospholes inspired us to study the coupling of 1Li with chlorodiazaphospholene 2, which led to the N‐substituted product 3. Reaction of 1Li with chlorodiphenyl‐ and chlorodicyclohexylphosphane likewise gave N‐phosphanylbenzazaphospholes 4 and 5, whereas with the more bulky di‐tert‐butyl‐ and di‐1‐adamantylchlorophosphanes, the diphosphanes 6 and 7 are obtained; in the case of 7 they are isolated as a dimeric LiCl(THF) adduct. Structural information was provided by single‐crystal X‐ray diffraction and solution NMR spectroscopy experiments. 2D exchange spectroscopy confirmed the existence of two rotamers of the aminophosphane 5 at room temperature; variable‐temperature NMR spectroscopy studies of 6 revealed two dynamic processes, low‐temperature inversion at ring phosphorus (ΔH≠=22 kJ mol−1, ΔS≠=2 J K−1 mol−1) and very low‐temperature rotation of the tBu2P group. Quantum chemical studies give evidence that 2‐unsubstituted benzazaphospholides prefer N‐phosphanylation, even with bulky chlorophosphanes, and that substituents at the 2‐position of the heterocycle are crucial for the occurrence of P–N rotamers and for switching to alternative P‐substitution, beyond a threshold steric bulk, by both P‐ and 2‐position substituents.
Preparation, Modification, and Evaluation of Cruentaren A and Analogues
Authors: Bindl Martin , Jean Ludovic , Herrmann Jennifer , Müller Rolf , Fürstner Alois 
Published: October 2009

AbstractAn expeditious total synthesis of the highly cytotoxic F‐ATPase inhibitor cruentaren A (1) is described based on a ring‐closing alkyne metathesis (RCAM) reaction for the formation of the macrocylic ring. Other key transformations comprise a C‐acylation of the benzyl lithium reagent derived from orsellinic acid ester9with Weinreb amide7, a CBS reduction of the resulting ketone10, and a Soderquist propargylation of aldehyde21with allenylborane (S)‐27to set the C‐15 chiral center of the required alcohol fragment25. The RCAM precursor33was assembled by acylation of25with acid fluoride32, since more conventional methods for ester bond formation were unproductive. Moreover, the choice of the protecting groups, in particular for the secondary alcohol at C‐9, which is prone to engage in translactonization, turned out to be critical; a relatively stable TBDPS ether had to be chosen for this site, which was removed in the final step of the synthesis with aqueous HF since other fluoride sources met with failure. The successful synthetic route was then expanded beyond the natural product, bringing a series of analogues into reach that feature incremental but deep‐seated structural modifications. Three of these fully synthetic compounds turned out to be as or even more cytotoxic than cruentaren A itself against L‐929 mouse fibroblast cells, reaching IC50values as low as 0.7 ng mL−1.